This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Anthera Pharmaceuticals Completes Interim Analysis Of PEARL-SC Clinical Trial With Blisibimod

HAYWARD, Calif., March 5, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases including cardiovascular and autoimmune disorders, today announced the continuation of the Phase 2b PEARL-SC clinical study following an interim analysis of all safety and efficacy data.

As part of the ongoing safety monitoring of the PEARL-SC clinical study, the Company's Data Safety Monitoring Board (DSMB) met for the fourth time since the beginning of the study to review all available patient safety data.  Following the analysis, the DSMB recommended the study proceed as planned without modification.

Concurrent with the DSMB review, an independent statistician completed an interim efficacy analysis after the 350th enrolled patient had reached the 24-week time-point in the study and recommended the study continue to completion.  Per the clinical study protocol, the independent statistician could have recommended an early stop to the study if the difference in efficacy between pooled treatment and placebo groups at 24 weeks and either the 16, 20, or 28-week time point met a pre-defined statistical threshold.  In December 2011, an independent review of the biomarker data confirmed that monthly and weekly subcutaneous doses of blisibimod resulted in statistically significant reductions of B-cells.

As a result of these recommendations, top-line efficacy data from the PEARL-SC clinical study is expected in the second quarter of 2012.  With 547 patients the study retains greater than 90% statistical power to detect a treatment difference of 14% with an associated p-value of less than 0.046 (p<0.046) for the study's primary endpoint*.

PEARL-SC (A randomized, double-blind Phase 2b study to evaluate the efficacy, safety, and tolerability of blisibimod administration in subjects with systemic lupus erythematosus) is examining the therapeutic benefit of weekly and monthly subcutaneous injections of blisibimod in patients with active and antibody positive systemic lupus erythematosus (SLE).  The clinical study enrolled 547 patients in 11 countries and 72 clinical sites worldwide. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.42 1.90%
FB $117.68 -0.75%
GOOG $690.28 -1.10%
TSLA $233.00 -3.60%
YHOO $35.84 -1.90%


Chart of I:DJI
DOW 17,628.94 -121.97 -0.69%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs